63 related articles for article (PubMed ID: 8151542)
1. [Lymphoproliferative lesions localized in the renal graft. A French multicenter study].
Renoult E; Kessler M
J Radiol; 1994 Jan; 75(1):53-6. PubMed ID: 8151542
[TBL] [Abstract][Full Text] [Related]
2. Post-transplant lymphoproliferative disorders after live donor renal transplantation.
Jain M; Badwal S; Pandey R; Srivastava A; Sharma RK; Gupta RK
Clin Transplant; 2005 Oct; 19(5):668-73. PubMed ID: 16146560
[TBL] [Abstract][Full Text] [Related]
3. Management and outcome of liver recipients with post-transplant lymphoproliferative disease.
Glez-Chamorro A; Jimenez C; Moreno-Glez E; Glez-Pinto I; Loinaz C; Gomez R; Garcia I; Alonso O; Palma F; Grande C
Hepatogastroenterology; 2000; 47(31):211-9. PubMed ID: 10690611
[TBL] [Abstract][Full Text] [Related]
4. Abdominal-pelvic lymphoproliferative disease after lung transplantation: presentation and outcome.
Hachem RR; Chakinala MM; Yusen RD; Lynch JP; Aloush AA; Patterson GA; Trulock EP
Transplantation; 2004 Feb; 77(3):431-7. PubMed ID: 14966421
[TBL] [Abstract][Full Text] [Related]
5. Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment.
Muti G; Cantoni S; Oreste P; Klersy C; Gini G; Rossi V; D'Avanzo G; Comoli P; Baldanti F; Montillo M; Nosari A; Morra E;
Haematologica; 2002 Jan; 87(1):67-77. PubMed ID: 11801467
[TBL] [Abstract][Full Text] [Related]
6. Posttransplantation lymphoproliferative disorder in liver recipients: characteristics, management, and outcome.
Ben-Ari Z; Amlot P; Lachmanan SR; Tur-Kaspa R; Rolles K; Burroughs AK
Liver Transpl Surg; 1999 May; 5(3):184-91. PubMed ID: 10226108
[TBL] [Abstract][Full Text] [Related]
7. [Carcinoma of the native kidney in patients with renal transplantation. A French multicenter study].
Renoult E; Kessler M
J Radiol; 1994 Jan; 75(1):49-52. PubMed ID: 8151540
[TBL] [Abstract][Full Text] [Related]
8. The morphologic and molecular genetic categories of posttransplantation lymphoproliferative disorders are clinically relevant.
Chadburn A; Chen JM; Hsu DT; Frizzera G; Cesarman E; Garrett TJ; Mears JG; Zangwill SD; Addonizio LJ; Michler RE; Knowles DM
Cancer; 1998 May; 82(10):1978-87. PubMed ID: 9587133
[TBL] [Abstract][Full Text] [Related]
9. Posttransplantation lymphoproliferative disorders in renal transplant recipients: report of over 20 years of experience.
Saadat A; Einollahi B; Ahmadzad-Asl MA; Moradi M; Nafar M; Pourfarziani V; Firoozan A; Porrezagholi F; Davoudi F
Transplant Proc; 2007 May; 39(4):1071-3. PubMed ID: 17524894
[TBL] [Abstract][Full Text] [Related]
10. Lymphoproliferative disorders and hematologic malignancies following organ transplantation.
Ferry JA; Jacobson JO; Conti D; Delmonico F; Harris NL
Mod Pathol; 1989 Nov; 2(6):583-92. PubMed ID: 2587566
[TBL] [Abstract][Full Text] [Related]
11. Anticancer effect of sirolimus in renal allograft recipients with de novo malignancies.
Boratyńska M; Watorek E; Smolska D; Patrzałek D; Klinger M
Transplant Proc; 2007 Nov; 39(9):2736-9. PubMed ID: 18021973
[TBL] [Abstract][Full Text] [Related]
12. Mycobacterium tuberculosis infection following renal transplantation in Taiwan.
Chen CH; Lian JD; Cheng CH; Wu MJ; Lee WC; Shu KH
Transpl Infect Dis; 2006 Sep; 8(3):148-56. PubMed ID: 16913973
[TBL] [Abstract][Full Text] [Related]
13. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
Hurwitz M; Desai DM; Cox KL; Berquist WE; Esquivel CO; Millan MT
Pediatr Transplant; 2004 Jun; 8(3):267-72. PubMed ID: 15176965
[TBL] [Abstract][Full Text] [Related]
14. [Epstein-Barr virus-associated posttransplant lymphoproliferative disease after renal transplantation].
Matsubara E; Yakushijin Y; Nomura T; Iwamasa K; Narumi H; Sakai I; Yasukawa M; Fujita S; Hato T; Ohshima K; Uno M
Rinsho Ketsueki; 2002 Oct; 43(10):949-53. PubMed ID: 12462032
[TBL] [Abstract][Full Text] [Related]
15. Acute renal allograft rejection in patients with Epstein-Barr virus associated post-transplant lymphoproliferative disorder.
Purighalla R; Shapiro R; Jordan ML; Scantlebury VP; Gritsch HA; Vivas C; Randhawa PS
Clin Transplant; 1997 Dec; 11(6):574-6. PubMed ID: 9408687
[TBL] [Abstract][Full Text] [Related]
16. Prospective evaluation of malignant neoplasms in cardiac transplant recipients uniformly treated with prophylactic antilymphocyte globulin.
Dresdale AR; Lutz S; Drost C; Levine TB; Fenn N; Paone G; del Busto R; Silverman NA
J Thorac Cardiovasc Surg; 1993 Dec; 106(6):1202-7. PubMed ID: 8246561
[TBL] [Abstract][Full Text] [Related]
17. Posttransplant lymphoproliferative disorders in renal allograft recipients: report of 53 cases of a French multicenter study. PTLD French Working Group.
Caillard S; Lachat V; Moulin B
Transpl Int; 2000; 13 Suppl 1():S388-93. PubMed ID: 11112039
[TBL] [Abstract][Full Text] [Related]
18. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
Sundberg AK; Rohr MS; Hartmann EL; Adams PL; Stratta RJ
Clin Transplant; 2004; 18 Suppl 12():61-6. PubMed ID: 15217410
[TBL] [Abstract][Full Text] [Related]
19. [Renal graft survival in patients with systemic lupus erythematosus].
Chew-Wong A; Soltero L; Diná E; Alvarez-Sandoval E; Alberú J; Gamba G; Correa-Rotter R
Rev Invest Clin; 2002; 54(1):21-8. PubMed ID: 11995403
[TBL] [Abstract][Full Text] [Related]
20. [Diffuse lymphoproliferative disease after renal transplantation and its relation with Epstein-Barr virus. Experience at one center].
Franco A; Jiménez L; Aranda I; Alvarez L; González M; Rocamora N; Olivares J
Nefrologia; 2002; 22(5):463-9. PubMed ID: 12497748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
